NASDAQ · IMUX
Immunic, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for IMUX: Nov 12, 2026
Immunic, Inc. Common Stock is estimated to report earnings on 11/12/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 7 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.82. The reported EPS for the same quarter last year was $-1.3.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.82 | $-0.74 | $-0.87 | 7 |
| Dec 2026 | $-0.80 | $-0.57 | $-1.16 | 7 |
| Mar 2027 | $-0.60 | $-0.55 | $-0.63 | 3 |
| Jun 2027 | $-0.62 | $-0.57 | $-0.66 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · RTTNews · Fintel · The Motley Fool- Zacks · Oct 22, 4:07 AM EDTNew Strong Buy Stocks for October 22ndBBCP, UCB, TGS, STX and IMUX have been added to the Zacks Rank #1 (Strong Buy) List on October 22, 2026.
- RTTNews · Oct 19, 12:31 PM EDTImmunic Names Jaa Roberson Chief People Officer(RTTNews) – On Monday, Immunic, Inc. (IMUX), a biotechnology company developing oral treatments for neurological diseases, appointed Jaa Roberson as Chief People Officer, effective immediately. She will report to CEO Erik Lundgren and join the executive leadership team.
- RTTNews · Aug 13, 10:01 AM EDTImmunic Posts Wider Q2 Loss; Expects Twin Phase 3 Results For Multiple Sclerosis By Year-End 2026(RTTNews) – Immunic, Inc. (IMUX) a late-stage biotech company, released financial results for the second quarter ended June 30, 2026, reporting a wider loss than a year ago, driven by higher operating expenses.
- Zacks · Aug 13, 9:55 AM EDTCan Immunic (IMUX) Climb 163.03% to Reach the Level Wall Street Analysts Expect?The mean of analysts' price targets for Immunic (IMUX) points to a 163% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- RTTNews · May 27, 6:51 AM EDTImmunic Names Erik Lundgren Chief Executive Officer(RTTNews) – Immunic, Inc. (IMUX), a late-stage biotechnology company, on Wednesday said it has appointed Erik Lundgren as its new chief executive officer, effective May 22, 2026, with employment set to begin on June 1.
- RTTNews · Apr 28, 6:50 AM EDTImmunic Appoints Michael Panzara As CMO(RTTNews) – Immunic, Inc. (IMUX), Tuesday announced the appointment of Michael Panzara, as Chief Medical Officer, succeeding Andreas Muehler, effective April 24, 2026.
- Fintel · Apr 28, 4:02 AM EDTImmunic (IMUX) Price Target Increased by 920.41% to 54.64The average one-year price target for Immunic (NasdaqCM:IMUX) has been revised to $54.64 / share. This is an increase of 920.41% from the prior estimate of $5.36 dated April 12, 2026. The price target is an average of many targets provided by analysts. The lat
- Fintel · Apr 17, 12:03 PM EDTStifel Initiates Coverage of Immunic (IMUX) with Buy RecommendationFintel reports that on April 17, 2026, Stifel initiated coverage of Immunic (NasdaqCM:IMUX) with a Buy recommendation. Analyst Price Forecast Suggests 435.50% Upside
- Fintel · Apr 9, 1:05 AM EDTImmunic (IMUX) Price Target Increased by 16.67% to 5.36The average one-year price target for Immunic (NasdaqCM:IMUX) has been revised to $5.36 / share. This is an increase of 16.67% from the prior estimate of $4.59 dated March 25, 2026. The price target is an average of many targets provided by analysts. The lates
- Fintel · Mar 24, 8:04 PM EDTGuggenheim Initiates Coverage of Immunic (IMUX) with Buy RecommendationFintel reports that on March 24, 2026, Guggenheim initiated coverage of Immunic (NasdaqCM:IMUX) with a Buy recommendation. Analyst Price Forecast Suggests 325.00% Upside
- The Motley Fool · Mar 24, 5:32 PM EDTStock Market Today, March 24: Oil, AI, and Private Credit Fears Weigh on MarketsThe S&P 500 (SNPINDEX:^GSPC) fell 0.37% to 6,556.37, and the Nasdaq Composite (NASDAQINDEX:^IXIC) dropped 0.84% to 21,761.89 on tech and software weakness. The Dow Jones Industrial Average (DJINDICES:^DJI) slipped 0.18% to 46,124.06 after a day of choppy, oil-driven trading.
- RTTNews · Feb 13, 8:26 AM ESTImmunic Announces $400M Oversubscribed Private Placement To Drive Commercial Shift; Stock Up(RTTNews) – Immunic, Inc. (IMUX) has announced an oversubscribed private placement of up to $400 million, a financing designed to support the company's transition from a late-stage R&D organization into a fully integrated commercial-stage biotechnology company.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Immunic, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.